Telavancin: a novel lipoglycopeptide antibiotic (Q37463589)

20 August 2017

1 reference

title

Telavancin: a novel lipoglycopeptide antibiotic (English)

1 reference

20 August 2017

Lisa Charneski

1

1 reference

20 August 2017

Priti N Patel

series ordinal

2

1 reference

20 August 2017

Donna Sym

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

28 April 2009

1 reference

Annals of Pharmacotherapy

20 August 2017

1 reference

20 August 2017

43

1 reference

20 August 2017

5

1 reference

20 August 2017

928-938

1 reference

Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria

20 August 2017

1 reference

Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

21 January 2018

1 reference

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

21 January 2018

1 reference

Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?

21 January 2018

1 reference

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

21 January 2018

1 reference

NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007

21 January 2018

1 reference

Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections

21 January 2018

1 reference

Telavancin: a novel lipoglycopeptide antimicrobial agent

21 January 2018

1 reference

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

21 January 2018

1 reference

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics

21 January 2018

1 reference

Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects

21 January 2018

1 reference

Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation

21 January 2018

1 reference

Tissue penetration of telavancin after intravenous administration in healthy subjects

21 January 2018

1 reference

In vitro activity of TD-6424 against Staphylococcus aureus

21 January 2018

1 reference

Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model

21 January 2018

1 reference

Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters

21 January 2018

1 reference

In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp

21 January 2018

1 reference

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States

21 January 2018

1 reference

In vitro activity of telavancin against resistant gram-positive bacteria

21 January 2018

1 reference

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative

21 January 2018

1 reference

Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus

21 January 2018

1 reference

Telavancin: in vitro activity against staphylococci in a biofilm model

21 January 2018

1 reference

Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

Wound microbiology and associated approaches to wound management

21 January 2018

1 reference

Foot infections in diabetic patients: the role of anaerobes

21 January 2018

1 reference

The increased prevalence of severe necrotizing infections caused by non-group A streptococci

21 January 2018

1 reference

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

21 January 2018

1 reference

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

21 January 2018

1 reference

Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects

21 January 2018

1 reference

Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1G417

1 reference

20 August 2017

1 reference